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Abstract
Objective
To investigate the use of muscle MRI for the diﬀerential diagnosis and as a disease progression
biomarker for 2 major forms of motor neuron disorders: spinal bulbar muscular atrophy
(SBMA) and amyotrophic lateral sclerosis (ALS).
Methods
We applied quantitative 3-point Dixon and semiquantitative T1-weighted and short tau in-
version recovery (STIR) imaging to bulbar and lower limb muscles and performed clinical and
functional assessments in ALS (n = 21) and SBMA (n = 21), alongside healthy controls (n =
16). Acquired images were analyzed for the presence of fat inﬁltration or edema as well as
speciﬁc patterns of muscle involvement. Quantitative MRI measurements were correlated with
clinical measures of disease severity in ALS and SBMA.
Results
Quantitative imaging revealed signiﬁcant fat inﬁltration in bulbar (p < 0.001) and limb muscles
in SBMA compared to controls (thigh: p < 0.001; calf: p = 0.001), identifying a characteristic
pattern of muscle involvement. In ALS, semiquantitative STIR imaging detected marked
hyperintensities in lower limb muscles, distinguishing ALS from SBMA and controls. Finally,
MRI measurements correlated signiﬁcantly with clinical scales of disease severity in both ALS
and SBMA.
Conclusions
Our ﬁndings show that muscle MRI diﬀerentiates between SBMA and ALS and correlates with
disease severity, supporting its use as a diagnostic tool and biomarker for disease progression.
This highlights the clinical utility of muscle MRI in motor neuron disorders and contributes to
establish objective outcome measures, which is crucial for the development of new drugs.
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Amyotrophic lateral sclerosis (ALS) and spinal bulbar mus-
cular atrophy (SBMA, also known as Kennedy disease) are
2 major motor neuron diseases (MNDs). ALS is a rapidly
progressive and fatal disorder characterized by relentless im-
pairment of motor function following the degeneration of
the upper and lower motor neurons (LMN).1 In SBMA LMN
degeneration, caused by an expanded cytosine-adenine-
guanine (CAG) repeat in the ﬁrst exon of the androgen re-
ceptor (AR) gene2 induces progressive disabling bulbar and
limb weakness at a slower rate.3 At disease onset, ALS and
SBMA may show similar symptoms, and distinguishing the 2
disorders is of paramount interest.4
There are no eﬀective disease-modifying therapies for either
ALS or SBMA, and, while promising targets for prospective
therapeutics have been identiﬁed,5 a serious limitation for
clinical trials is the shortage of sensitive and reliable outcome
measures for assessing disease progression.6
Skeletal muscle MRI can sensitively detect muscle involve-
ment in neuromuscular diseases7,8 and diﬀerentiate distinct
pathologic features, such as muscular fat inﬁltration or in-
tramuscular edema9 associated with acute denervation.10
Muscle MRI demonstrated promise as a biomarker of disease
progression in both myopathies and neuropathies.11
In this study, we investigated muscle MRI in SBMA and ALS
by studying the lower limb and the head–neck regions, which
are characteristically aﬀected in both disorders. We report that
muscle MRI can diﬀerentiate between both diseases. More-
over, we show that quantitative muscle MRI measures cor-
relate with the clinical severity of disease, thus supporting
their validity as outcome measures for quantifying disease
progression in clinical trials.
Methods
Study design and patient recruitment
We performed a prospective cross-sectional study assessing
muscular MRI of the head–neck region and lower limbs in 21
consecutive men with SBMA and 21 consecutive male and
female patients with ALS who were attending the national
Kennedy disease clinic and MND clinic at the National
Hospital for Neurology and Neurosurgery, Queen Square,
London, UK, between 2015 and 2017. Patients with geneti-
cally conﬁrmed mutation of AR gene were included in the
SBMA group. Patients eligible for the ALS group all presented
with a history of at least clinically possible disease according to
revised El Escorial criteria.12
In addition, 16 healthy controls comparable to the patient
groups concerning their demographic data were recruited as
a control group. Diﬀerences in sex prevalence in the ALS and
SBMA groups were taken into account, where for compar-
isons with patients with ALS both female and male healthy
volunteers were considered, whereas patients with SBMA
were compared to male healthy controls only. General ex-
clusion criteria for all participants were concomitant neuro-
muscular diseases and safety-related MRI contraindications.
Data from 1 patient with ALS and 1 patient with SBMA were
excluded from any further analysis due to incomplete scan
examination. After MRI examinations were completed, in
the SBMA group data from 3 patients had to be excluded
due to insuﬃcient image quality in the head–neck region.
Two patients’ data were excluded for the same reason from
the ALS group. In addition, in 1 healthy control, head–neck
imaging could not be acquired due to inability to tolerate
lying still in the MRI scanner for the required examination
time.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the London–Queen Square Re-
search Ethics Committee (11/LO/1425). Written informed
consent was obtained from all participants in the study.
Data acquisition
Clinical and functional testing
All participants were functionally rated using the ALS Func-
tional Rating Scale–Revised (ALSFRS-R).13 In patients with
SBMA, functional state was additionally scored according to
the SBMA Functional Rating Scale (SBMA-FRS)14 and sup-
plementary measurements with the recently introduced adult
myopathy assessment tool (AMAT) were performed.15 All
participants underwent detailed assessment including medical
history and an examination of the clinical and neurologic
status.
Glossary
ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale–Revised; AMAT = adult myopathy assessment
tool; AR = androgen receptor; BFP = biceps femoris posterior; CMC = calf muscle compartments; CSA = cross-sectional area;
FFall = overall mean muscle fat fraction; FFmsc = mean muscle-speciﬁc fat fraction; fRMAmsc = functional remaining muscle
area;GG = genioglossus;GH = geniohyoideus;HG = hyoglossus; IQR = interquartile range; LG = gastrocnemius lateralis; LL =
lower limb; LMN = lower motor neuron;MG = gastrocnemius medialis;MH = mylohyoideus;MND = motor neuron disease;
PL = peroneus longus; RF = rectus femoris; SBMA = spinal bulbar muscular atrophy; SBMA-FRS = SBMA Functional Rating
Scale; SM = semimembranosus; SO = soleus; ST = semitendinosus; STIR = short tau inversion recovery; TA = tibialis anterior;
TMC = thigh muscle compartment; TP = tibialis posterior; VI = vastus intermedius; VL = vastus lateralis.
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Magnetic resonance imaging
Images of the participants’ head–neck, thighs, and calves
were acquired at 3T (Siemens Healthineers, Erlangen,
Germany). Quantitative fat-fraction maps were produced
using the 3-point Dixon technique,16 and T1-weighted
images, used for qualitative assessment, were acquired for all
3 regions. In addition, fat-suppressed T2-weighted short tau
inversion recovery (STIR) images were acquired of the thighs
and calves. In total, imaging of all 3 regions took approximately
35 minutes.
MRI data analysis
Semiquantitative muscle MRI analysis
Muscle fat inﬁltration and edema, as visualized on the T1- and
STIR-weighted images, respectively, were assessed and rated
in consensus by 2 readers (U.K., K.T.) blinded to clinical
diagnosis, after appropriate training. T1-weighted images
were visually scored using the 6-point Mercuri scale17 (0 =
normal, 1 = mild fatty streaks, 2a = early conﬂuence, 2b = fatty
inﬁltration 30%–60%, 3 = fatty inﬁltration >60%, 4 = com-
plete fat replacement). The presence of hyperintensities in the
STIR-weighted images in the thighs and calves were visually
scored on a 3-point scale as proposed byMorrow18 (0 = none,
1 = mild, 2 = marked).
In the head-neck region the following bulbar muscles were
rated on the Mercuri scale: mastication muscles comprising
pterygoideus medialis (Pm); pterygoideus lateralis (Pl);
temporalis (TE); masseter (MA); swallowing muscles com-
prising buccinator (BU); orbicularis oris (OO); digastricus
(Da/p - venter anterior/venter posterior); levator veli palatini
(LvP); tensor veli palatini (TvP); and intrinsic and extrinsic
tongue muscles comprising genioglossus (GG). geniohyoi-
deus (GH); hyoglossus (HG); mylohyoideus (MH).
Bilaterally, lower limb muscles were assessed on both the
Mercuri and Morrow scales, and included anterior thigh
compartment comprising rectus femoris (RF), vastus lateralis
(VL), vastus intermedius (VI), and vastus medialis (VM);
posterior thigh compartment comprising biceps femoris (long
head) and biceps femoris (short head) as one muscle (BFP);
semitendinosus (ST); semimembranosus (SM); medial thigh
compartment comprising adductor magnus (AM), sartorius
(S), and gracilis (G); anterior calf compartment comprising
tibialis anterior (TA; including extensor hallucis longus);
lateral calf compartment comprising peroneus longus (PL);
superﬁcial posterior calf compartment comprising gastroc-
nemius lateralis (LG) and gastrocnemius medialis (MG); and
deep posterior calf compartment comprising the soleus (SO;
including ﬂexor digitorum longus and ﬂexor hallucis longus)
and tibialis posterior (TP).
Quantitative muscle MRI analysis
A single observer (U.K.) blinded to study groups outlined the
muscles in the thighs, calves, and bulbar region using ITK-
SNAP software.19 These regions were used to calculate the
mean fat fraction (FFmsc) and cross-sectional area (CSA) for
each muscle and muscle compartment. In addition,
a weighted overall mean muscle fat fraction (FFall) was cal-
culated at each level using the following:
FFall =
+2i = 1+
m
j = 1nij×FFij
+2i = 1+
m
j = 1nij
(1)
with i: 1 = left, 2 = right;m = total number of muscle regions of
interest at each level.
Here nij is the number of voxels in muscle j. The MRI-based
functional remaining muscle area (fRMAmsc), deﬁned as the
CSA of the muscle tissue not replaced by fat, was calculated
using the following:
fRMA =
CSA × ð100 − FFÞ
100
(2)
Statistical analysis
Statistical analyses were performed with SPSS version 22
(SPSS, Armonk, NY) with an α level of 0.05. As appropriate
to the distribution of data, measures are reported as mean ±
SD or median and interquartile range (IQR). For intergroup
comparisons, Kruskal-Wallis tests, 2-sample t tests, and
Mann-Whitney U tests were applied as appropriate. Missing
data were excluded from analyses. Correlations of MRI data
with clinical measures were investigated with Spearman (ρ)
or Pearson coeﬃcients as appropriate for the distribution of
data.
Data availability statement
Anonymized data of this study will be shared by request from
any qualiﬁed investigator.
Results
Participant demographics and clinical findings
The study included 2 patient groups, SBMA (n = 21) and
ALS (n = 21), along with healthy controls (n = 16). For
analysis exclusion criteria, see Methods. Mean age was 50.7
(SD 17) years and 54.4 (SD 14.6; p = 0.53) years in the
SBMA and SBMA control group, respectively (table 1).
Mean age was 57.3 (SD 14.8) years and 55.4 (SD 13.5; p =
0.69) years in the ALS and ALS control group, respectively.
Height and weight did not signiﬁcantly diﬀer between the 2
patient groups and controls, except for patients with ALS
having a signiﬁcantly lower body mass index compared to
their control group (p = 0.009). In both patient groups,
ALSFRS-R and its lower limb (LL) subscale scores were
similar (ALSFRS-R total score, SBMA: 42 [31–48], ALS: 41
[28–47]; ALSFRS-R LL subscore, SBMA: 5 [2–8], ALS: 5.5
[3–8]; ALSFRS-R bulbar subscore, SBMA: 10.5 [9–12],
ALS: 12 [5–12]) and signiﬁcantly reduced compared to
healthy controls (SBMA vs controls; p < 0.001, ALS vs
controls; p < 0.001; table 1).
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Thigh muscle fat infiltration differentiates
SBMA fromALS and defines specific patterns of
muscle involvement
To assess the pattern and the severity of muscle fat in-
ﬁltration in SBMA and ALS, we acquired T1-weighted10 and
quantitative 3-point Dixon11 MRI from LL muscles. We
rated the T1-weighted images according to the Mercuri
scale.17 While whole-thigh SBMA Mercuri scores were sig-
niﬁcantly increased compared to controls (median 2, IQR 1
vs median 1, IQR 0; M-W-U = 10, p < 0.001), there was no
diﬀerence in ALS compared to controls (median 1, IQR 0 vs
median 1, IQR 0; M-W-U = 130, p = 0.35; ﬁgure 1B). We
identiﬁed a previously unrecognized pattern of muscle in-
volvement in the SBMA patient group, aﬀecting both ante-
rior and posterior thigh muscle compartments (TMC) with
relative sparing of the medial TMC. Speciﬁcally, the VL and
the SM were the most severely aﬀected muscles in the an-
terior and posterior TMC, while in the medial TMC no
muscle showed severe involvement (Mercuri grade 4). In
contrast to SBMA, no patient with ALS showed severe
muscle fat involvement by scoring Mercuri grade 3 or 4 in
any of the TMC (ﬁgure 1B).
FFall at mid-thigh level was signiﬁcantly higher in both patient
groups compared to the matched control group (SBMA vs
controls: median 7.9%, IQR 17.93% vs median 1.67%, IQR
0.85%; M-W-U = 12; p < 0.001; ALS vs controls: median
2.79%, IQR 1.13% vs median 1.79%, IQR 0.98%; M-W-U =
75; p = 0.006; ﬁgure 2A). FFmsc conﬁrmed the pattern
identiﬁed in the semiquantitative assessments: in patients
with SBMA, the highest FFmsc was observed in the posterior
TMC (BFP, followed by ST and SM; ﬁgure 2D) and in the
anterior TMC (VL, followed by VI and RF; ﬁgure 2B); the
medial TMC was relatively spared, with the lowest FFmsc in
patients with SBMA (ﬁgure 2C). Despite a signiﬁcantly higher
overall FFall compared to their matched controls, no speciﬁc
pattern of fat inﬁltration was observed on single muscle
analysis in patients with ALS. However, there was signiﬁcant
atrophy of thigh muscles in patients with ALS compared to
controls (table 2).
Overall, widespread intramuscular fat accumulation was
observed in patients with SBMA, occurring with a prefer-
ential involvement of muscles in the anterior and poste-
rior TMC.
Table 1 Demographic and clinical data of patients with spinal bulbar muscular atrophy (SBMA), patients with
amyotrophic lateral sclerosis (ALS), and controls
Demographics and
clinical measures
SBMA
(n = 20)
Control group
for patients
with SBMA (n = 11) p Value
ALS
(n = 20)
Control group
for patients
with ALS (n = 16) p Value
Sex, M/F 20/0 11/0 NA 14/6 11/5 0.61
Handedness, R/L 17/3 11/0 0.18 19/1 15/1 0.87
Age, y 50.7 (17.0) 54.4 (14.6) 0.53 57.3 (14.8) 55.4 (13.5) 0.69
Height, cm 176.6 (6.7) 175.7 (4.5) 0.65 174.5 (13.8) 172.8 (5.9) 0.63
Weight, kg 87.5 (17.0) 85.0 (11.8) 0.64 70.2 (13.1) 79.1 (13.9) 0.06
BMI 28.02 (5.0) 27.6 (4.0) 0.79 23.0 (3.0) 26.4 (4.0) 0.009
Disease duration, y 8.5 (1–33) NA NA 1.75 (0.5–10) NA NA
ALSFRS-R total 42 (31–48) 48 (47–48) <0.001 41 (28–47) 48 (47–48) <0.001
ALSFRS-R lower limbs 5 (2–8) 8 (8) <0.001 5.5 (3–8) 8 (8) <0.001
ALSFRS-R bulbar 10.5 (9–12) 12 (11–12) <0.001 12 (5–12) 12 (11–12) 0.09
SBMA-FRS total 43.0 (7.8) NA NA NA NA NA
SBMA-FRS lower limbs 4.4 (2.3) NA NA NA NA NA
SBMA-FRS bulbar 15.8 (2.8) NA NA NA NA NA
AMAT score 33.6 (8.2) NA NA NA NA NA
Bulbar involvement (yes/no) 13/7 NA NA 8/12 0/16 0.005
Riluzole therapy (yes/no) 0/20 NA NA 15/5 0/16 NA
Abbreviations: ALSFRS-R = ALS Functional Rating Scale–Revised; AMAT = adult myopathy assessment tool; BMI = body mass index; SBMA-FRS = SBMA
Functional Rating Scale.
Data are presented as mean (SD) or median (range) as appropriate to distribution of the data.
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Figure 1 Semiquantitative muscle MRI analysis: T1-weighted imaging
(A) Thigh muscle compartments and individual thighmuscles of a healthy control (CTR), superimposed on a fat fraction (FF) map. (B) Corresponding axial T1-
weighted sample images (upper row) of the right and left thigh in spinal bulbar muscular atrophy (SBMA) (left), amyotrophic lateral sclerosis (ALS) (middle),
and healthy CTR (right). Mercuri scores (lower row) are higher in the SBMA group compared to the CTR group (M-W-U = 10, p < 0.001). (C) Calf muscle
compartments (CMC) and individual calfmuscles of a healthy control, superimposed on a FFmap. (D) Corresponding axial T1-weighted sample images (upper
row) of the right and left calf in SBMA (left), ALS (middle), and CTR (right). Mercuri scores (lower row) are higher in both patient groups compared to their
matched CTR group (SBMA vs CTR: M-W-U = 10, p = 0.001; ALS vs CTR: M-W-U = 130, p = 0.008).
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Calfmuscle fat infiltration differentiates SBMA
from ALS and defines specific patterns of
muscle involvement
Mercuri scores for calf T1-weighted images were signiﬁcantly
altered in both patients with SBMA and patients with ALS
compared to their matched controls (SBMA vs controls:
median 3, IQR 1.88 vs median 1, IQR 0; M-W-U = 10, p =
0.001; ALS vs controls: median 1.5, IQR 1 vs median 1, IQR
0; M-W-U = 130, p = 0.008; ﬁgure 1D). Patients with SBMA
showed a previously nondescribed pattern of muscle in-
volvement with relative sparing speciﬁcally of the TA and TP
muscles and predominant involvement of the superﬁcial and
deep posterior calf muscle compartments (CMC), with more
than 50% of patients scoring Mercuri grade 3 or 4 in MG, SO,
and LGmuscles. Conversely, none of the patients with ALS or
healthy controls had Mercuri grade 3 or 4 in any of the CMC.
However, more than 70% of patients with ALS showed
moderate fatty degeneration (Mercuri grade 2a or 2b) in the
lateral CMC, aﬀecting mostly the PL.
Quantitatively, FFall were higher in both patient groups
compared to controls, albeit with much lower levels in ALS
(SBMA vs controls: median 14.54%, IQR 38.17% vs median
1.87%, IQR 1.23%; M-W-U = 31; p = 0.001; ALS vs controls:
median 3.34%, IQR 2.07% vs median 1.92%, IQR 1.08%;
M-W-U = 69; p = 0.003; ﬁgure 2A). Analysis of the FFmsc
conﬁrmed the semiquantitative ﬁndings of predominant
posterior CMC aﬀection and sparing of TA and TP in SBMA
patient group. At calf level, the highest FFmsc were found in
the superﬁcial posterior CMC. Although FFmsc of speciﬁc calf
muscles were generally lower in ALS than SBMA, in keeping
with semiquantitative ﬁndings, the lateral CMC showed the
highest FFmsc within patients with ALS (ﬁgure 2B). Com-
pared to controls, signiﬁcant atrophy of calf muscles in
patients with ALS was observed (table 2).
Overall, widespread intramuscular fat accumulation, occur-
ring with a speciﬁc pattern relatively sparing the TA and TP
muscles and more severely aﬀecting the posterior compart-
ment muscles, was observed in the patients with SBMA. ALS
also showed changes, albeit at lesser levels, and with a dif-
ferent pattern, the lateral compartment being the most
aﬀected.
Fat-suppressed STIR images show specific
changes in both SBMA and ALS
As the rapid course of ALSmay contribute to the modest level
of fat inﬁltration in this condition, we investigated whether
semiquantitative fat-suppressed STIR sequences would reveal
more identiﬁable changes deriving from quickly developing
muscle denervation. Marked STIR hyperintensities were ob-
served in almost all TMC and CMC in both patient groups
compared to their age-matched controls.
Using the rating scale proposed by Morrow et al.,18 marked
muscle tissue hyperintensities (Morrow grade 2) were
detected in the anterior and posterior TMC of patients with
SBMA (ﬁgure 3A); in the calves of patients with SBMA, STIR
abnormalities were observed in all muscle compartments
(ﬁgure 3B). In the ALS patient group, the anterior TMC was
the most altered, although signal abnormalities were
detected in every CMC. In healthy controls, no marked
hyperintensities were observed in any of the TMC, while in
the calf, we noticed STIR signal hyperintensities of MG,
previously described as “central stripe,” 10 which corre-
sponds to the muscle end‐plate region of this muscle
(ﬁgure 3B).
Overall, diﬀerently from T1-weighted sequences, STIR
sequences detect changes in both conditions, with alterations
in the calves being more marked in ALS.
Table 2 Quantitative MRI measures of patients with spinal bulbar muscular atrophy (SBMA), patients with amyotrophic
lateral sclerosis (ALS), and controls
Quantitative imaging
measures
SBMA
(n = 20)
Control group for
patients with
SBMA (n = 11) p Value ALS (n = 20)
Control group for
patients with
ALS (n = 16) p Value
MRI, thigh level
FFall, % 7.9 (1.7–68.2) 1.7 (1.3–3.1) <0.001 2.8 (1.6–4.6) 1.8 (1.3–4.4) 0.17
Total CSA thighs, mm2 23,119.6 (4,986.9) 26,431.5 (5,479.1) 0.11 18,205.2 (5,851.4) 23,711.8 (6,246.0) 0.01
MRI, calf level
FFall, % 14.5 (1.4–72.1) 1.9 (1.6–6.0) 0.001 3.4 (1.7–12.0) 1.9 (1.6–6) 0.003
Total CSA calves, mm2 14,566.8 (3,576.3) 16,121.4 (3,649.3) 0.28 11,235.0 (3,325.1) 14,801.9 (3,645.2) 0.006
MRI, tongue level n = 17 n = 10 n = 18 n = 15
FFall, % 21.7 (3.9–52.0) 6.6 (2.8–25.3) <0.001 8.7 (3.3–28.7) 6.8 (2.8–25.3) 0.09
Abbreviations: CSA = cross-sectional area; FFall = overall muscle fat fraction percentage.
Data are presented as mean (SD) or median (range) as appropriate to distribution of the data.
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Muscle MRI detects widespread muscle
changes at bulbar level in SBMA
Although bulbar muscles are aﬀected in both SBMA and
ALS, these have rarely been included in previous muscle
MRI studies.20,21 We therefore assessed fatty changes of bulbar
muscles using both T1-weighted and 3-point Dixon sequences.
T1-weighted imaging showed a moderate to severe in-
volvement (Mercuri grade 2b–4) of mastication and
swallowing muscles in SBMA, while in contrast, patients
with ALS showed predominantly only mild to moderate
muscle fat inﬁltration of these muscle groups (Mercuri
grade 1–2b; ﬁgure 4B). Both patient groups showed
Figure 2 Quantitative muscle imaging: Thigh and calf muscle compartments
(A) Overall muscle fat fraction per-
centage (FFall) at thigh level (left) and
calf level (right) in spinal bulbar mus-
cular atrophy (SBMA), amyotrophic
lateral sclerosis (ALS), and controls
(CTR). Boxes represent median and
confidence interval (CI), whiskers show
range. FFall is significantly increased at
thigh and calf level in SBMA and ALS
groups compared to their age-
matched controls (thigh: SBMA vs CTR:
M-W-U = 12, p < 0.001; ALS vs CTR: M-
W-U = 75, p = 0.006; calf: SBMA vs CTR:
M-W-U = 31, p = 0.001; ALS vs CTR: M-
W-U = 69, p = 0.003). (B) Muscle-spe-
cific fat fraction (FFmsc) of right anterior
thigh muscle compartments (TMC)
(left) and right anterior/lateral calf
muscle compartments (CMC) (right).
(C) FFmsc of right medial TMC (left) and
right posterior superficial CMC (right).
(D) FFmsc of right posterior TMC (left)
and right posterior deep CMC (right).
Data are shown as dot plots with
boxes representing mean and whisk-
ers representing 95% CI. Asterisks in-
dicate p values of post hoc pairwise
comparisons between study groups
of Kruskal-Wallis test results for each
right thigh muscle. *0.05; **0.005;
***0.0005; ****<0.0001. AM = ad-
ductor magnus; BFP = biceps femoris
posterior; G = gracilis; LG = gastroc-
nemius lateralis; MG = gastrocnemius
medialis; PL = peroneus longus; RF =
rectus femoris; S = sartorius; SM =
semimembranosus; SO = soleus;
ST = semitendinosus; TA = tibialis
anterior; TP = tibialis posterior; VI =
vastus intermedius; VL = vastus lat-
eralis; VM = vastus medialis.
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moderate to severe involvement (Mercuri 2b or higher) of
intrinsic and extrinsic tongue muscles, including the GG,
GH, HG, and MH. Notably, 12.5% of healthy controls also
showed moderate muscle fat inﬁltration (Mercuri grade
2b) in extrinsic tongue muscles (ﬁgure 4B). Quantitative
FFall were signiﬁcantly higher in patients with SBMA
(median 21.69%, IQR 16.66%), compared to their
matched controls (median 6.63, IQR 3.50; M-W-U = 18; p
< 0.001; ﬁgure 4C). FFmsc were highest in the intrinsic
tongue muscles, followed by extrinsic tongue muscles GG
(median 16.56%, IQR 16%) and GH (median 10.29%, IQR
15%) in patients with SBMA. No signiﬁcant diﬀerence in
FFall was seen between patients with ALS (median 8.68%,
IQR 5.74%) and their matched controls (median 6.76%,
IQR 2.84%; M-W-U = 94; p = 0.15; ﬁgure 4C).
Overall, fat inﬁltration in bulbar muscles is able to diﬀerentiate
SBMA from both ALS and controls.
Figure 3 Semiquantitative muscle MRI analysis: Short tau inversion recovery (STIR) imaging
(A) Corresponding sample STIR axial images (upper row) of the right and left thigh in spinal bulbar muscular atrophy (SBMA) (left), amyotrophic lateral
sclerosis (ALS) (middle), and controls (CTR) (right). Proportion of Morrow scores (lower row) of thigh muscle compartments in all study groups. STIR
hyperintensities were observed in both patient groups. No marked signal abnormalities were observed in healthy controls. (B) Corresponding sample STIR
axial images (upper row) of the right and left calf in SBMA (left), ALS (middle), and CTR (right). Proportion of Morrow scores (lower row) of calf muscle
compartments in all study groups. STIR hyperintensities were observed in both patient groups. Apart from MG, no STIR hyperintensities were observed in
controls. AM = adductor magnus; BFP = biceps femoris posterior; G = gracilis; LG = gastrocnemius lateralis; MG = gastrocnemius medialis; PL = peroneus
longus; RF = rectus femoris; S = sartorius; SM = semimembranosus; SO = soleus; ST = semitendinosus; TA = tibialis anterior; TP = tibialis posterior; VI = vastus
intermedius; VL = vastus lateralis; VM = vastus medialis.
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Figure 4 Semiquantitative and quantitative muscle MRI analysis: Head and neck region
(A) T1-weighted sample images of head and neck muscles of spinal bulbar muscular atrophy (SBMA) (upper row left) and amyotrophic lateral sclerosis (ALS)
(upper rowmiddle). Regions of interest of intrinsic and extrinsic tonguemuscles derived from the unprocessed shortest echo time (TE)–Dixon sequence (TE =
3.45 ms) of healthy control (CTR) (upper row right). Sagittal T1-weighted sample images of tongue muscles of SBMA (lower row left), ALS (lower rowmiddle),
and CTR (lower row right). (B) Proportion of Mercuri scores of bulbar muscles in all study groups. Mercuri scores of bulbar muscles are higher in the SBMA
group and ALS group compared to their matched CTR group (SBMA vs CTR: M-W-U = 21, p < 0.001; ALS vs CTR: M-W-U = 90, p = 0.03). (C) Overall muscle fat
fraction percentage (FFall) of tongue muscles in SBMA, ALS, and CTR (left). Boxes represent median and confidence interval; whiskers show range. FFall is
significantly higher in SBMA compared to controls (M-W-U = 18, p < 0.001). Muscle-specific fat fraction (FFmsc) of intrinsic (IM) and extrinsic (genioglossus [GG]
and geniohyoideus [GH]) tonguemuscles in SBMA, ALS, and CTR (right). Asterisks indicate p values of post hoc pairwise comparisons between study groups of
Kruskal-Wallis test results for each tongue muscle. *0.05; **0.005; *** 0.0005; ****<0.0001.
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Muscle MRI correlates with functional rating
scales in MND
In order to test whether the MRI ﬁndings reﬂected disease
severity, we calculated correlations between muscle MRI
measures and functional measures, using established clinical
rating instruments for each condition: the ALSFRS-R for
patients with ALS and the SBMA-FRS and the AMAT score
for SBMA.
We initially asked whether the overall mean FFall of combined
thigh and calf level correlated with the LL subscale from
ALSFRS-R and found there was a strong negative correlation
between FFall and disability in patients with SBMA (ρ = −0.86,
p < 0.001) and a signiﬁcant negative correlation also in
patients with ALS (ρ = −0.47, p = 0.04; ﬁgure 5A). In SBMA,
the FFall strongly negatively correlated with the total AMAT
score (ρ = −0.77, p < 0.001; ﬁgure 5C). It is important to note
that FFall did not correlate with age in healthy controls
(ρ = −0.06, p = 0.8).
Since our results show that fat inﬁltration is not a prominent
feature in ALS while active denervation changes are occurring,
we next asked whether assessment of the fRMAmsc would take
muscle atrophy into account and provide a better measure for
ALS. Indeed, in patients with ALS, the fRMAmsc correlated
strongly with ALSFRS-R LL subscales (ρ = 0.68, p = 0.02;
ﬁgure 5B). The combined thigh and calf level fRMAmsc of
patients with SBMA also correlated strongly with SBMA-FRS
LL subscales (ρ = 0.70, p = 0.003) and with the AMAT score
(r = 0.58, p = 0.009; ﬁgure 5C).
Overall, MRI measures correlate with functional measures in
both SBMA and ALS, supporting their exploration as quan-
titative biomarkers of disease progression.
Figure 5 Correlation of muscle MRI measures with functional rating scales
(A) Overall muscle fat fraction per-
centage (FFall) of lower limb (LL)
shows a significant correlation with
ALS Functional Rating Scale–Revised
(ALSFRS-R) LL subscale in both pa-
tient groups (left: spinal bulbar
muscular atrophy [SBMA]: ρ = −0.86,
p < 0.001; right: amyotrophic lateral
sclerosis [ALS]: ρ = −0.47, p = 0.04).
(B) Functional remaining muscle
area (fRMA) of LL shows a significant
correlation with ALSFRS-R LL sub-
scale in both patient groups (left:
SBMA: ρ = 0.65, p = 0.003; right: ALS:
ρ = 0.68, p = 0.02). (C) FFall of LL cor-
relates significantly with adult my-
opathy assessment tool (AMAT)
score in patients with SBMA (left: ρ =
−0.77, p < 0.001). Significant corre-
lations were observed between
fRMA of LL and AMAT score in
patients with SBMA (right, r = 0.58, p
= 0.009).
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Discussion
In the present study, we performed skeletal muscle MRI on
cohorts of 2 major forms of adult MND: ALS and SBMA.
Furthermore, for the ﬁrst time, we also extended quantitative
fat fraction quantitation protocols to the head and neck re-
gion, given the involvement of bulbar muscles in these dis-
eases. In general, we show signiﬁcant fat inﬁltration of bulbar
and limbmuscles in SBMA andmarked STIR hyperintensities
in lower limb muscles in patients with ALS. Quantitative MRI
measurements strongly correlate with clinical measures of
disease severity in both groups.
The results of our study have important clinical relevance;
they identify a novel pattern of muscle involvement and show
that quantitative and semiquantitative skeletal muscle MRI
can diﬀerentiate ALS from SBMA. In addition, they support
the validity of muscle MRI as a disease progression biomarker,
as we show that MRI-quantiﬁed muscle FF and fRMA cor-
relate with clinical measures of both diseases.
Muscle MRI studies in ALS22,23 and SBMA24 have mostly
been limited to a small number of cases and have not included
quantitative assessments.25 Recently, Dahlqvist et al.26 pub-
lished results further supporting the validity of Dixon imaging
in SBMA. We have studied cohorts of substantial size, using
qualitative and quantitative MRI methods previously vali-
dated in other neuromuscular disease patient groups. Im-
portantly, while a focused analysis of the lower limbs was
appropriate for such conditions, we also developed re-
producible protocols demonstrating the feasibility and po-
tential value of extending MRI investigations to bulbar
muscles, which are crucially involved in ALS and SBMA.
While EMG is a rather restricted technique due to its invasive
nature and requires complete relaxation of the tongue for
appropriate recording,27 muscle MRI can be used to in-
vestigate speciﬁc anatomical regions at the bulbar level.
Our results suggest that diﬀerent muscle changes occur in
ALS and SBMA, with SBMA showing marked fat inﬁltration
on T1-weighted MRI, while in ALS, increased edema seen on
STIR images is the most prominent feature.
These ﬁndings are in line with previous observations, showing
that slowly progressive neuromuscular diseases can be assessed
more appropriately on T1-weighted images, while STIR im-
agingmay detect earliermuscle pathologies such as denervation
processes, before fat inﬁltration develops and becomes evi-
dent.28 Muscle denervation is a common pathologic feature in
ALS,29 and the increase in extracellular ﬂuid within the de-
nervated muscle30 is sensitively reﬂected by hyperintensities on
T2-weighted fat-suppressed MRI sequences such as STIR.
Using whole-body MRI, Jenkins et al.31 recently reported
higher relative T2 muscle signals in ALS compared to controls,
which correlated with clinical weakness and lower motor unit
number. In accord with these ﬁndings, we observed marked
STIR hyperintensities in all thigh and calf muscles in both
SBMA and ALS, highlighting the potential of fat-suppressed
MRI sequences to reveal changes deriving from muscle de-
nervation in the rapid course of disease progression in ALS.
Furthermore, we have identiﬁed consistent patterns of muscle
involvement and sparing in SBMA. Thus, fat accumulation
was observed predominantly in the posterior muscle compart-
ment at thigh and calf level (with relative sparing of the medial
thigh compartment and anterior calf compartment), and both
intrinsic and extrinsic muscles at tongue level. SBMA and ALS are
in diﬀerential diagnosis and approximately 13% of patients with
SBMA have been reported to have previously been given a di-
agnosis of ALS.32,33 Our ﬁndings support the use of muscle MRI
in the diagnostic workup of patients with prevalent LMN in-
volvement and suspected MND. Of note, although FF for all
lower limb muscles is signiﬁcantly increased in SBMA, in the least
aﬀectedmuscles there is a strong overlapwith healthy controls and
patients with ALS, underlining the importance of deﬁning muscle
patterns of involvement for clinical diagnostic applications.
Importantly, we also show that the MRI-obtained fRMAmsc
correlates with established clinical measures of disease pro-
gression in both diseases. Functional RMA takes into account
both the FFmsc of muscles, which is crucial in SBMA, and the
muscle atrophy that is typical of ALS. Indeed, while FFall does
signiﬁcantly correlate to functional scales in ALS, the eﬀect size
is small, and longitudinal studies will be needed to assess the
utility of FF measurements in ALS. The ability of MRI changes
to reﬂect clinical involvement supports their future use as dis-
ease progression biomarkers. There is currently an intensive
search for biomarkers of disease progression in MND in order
to carry out more eﬀective clinical trials.6 SBMA is slowly
progressive and rare, and more reliable, quantitative outcome
measures would reduce the duration as well as the size, and cost,
of clinical trials. Survival has often been used in ALS trials,34 but
novel sensitive outcome measures in ALS would also enable
shorter trials to be undertaken, reducing costs and allowingmore
therapies to be tested. Muscle MRI appears to fulﬁl the criteria
for such a biomarker, due to its reproducibility, its capability of
generating quantitative measurements, and its observer in-
dependence.35 Furthermore, fat inﬁltration or denervation-
related changes detected by muscle MRI may provide the
ground for the development of neurochemical markers, which
reﬂect these changes. However, further studies will be necessary
to assess the sensitivity of muscle MRI to detect progressive
changes in these diseases and to determine the full potential of
muscle MRI as a reliable outcome measure for ALS and SBMA.
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